Clinical Trials for Women’s Cancers

Medical College of Wisconsin physicians who specialize in gynecologic cancers collaborate with researchers and academic medical centers around the country to advance the understanding and treatment of ovarian, cervical, uterine, vulvar and vaginal cancers. Their patients – and the entire region – are the direct beneficiaries of ongoing research.

The Gynecologic Cancer Program is an active member of the Gynecologic Oncology Group (GOG), an organization that coordinates multi-center clinical trials to advance the treatment of gynecologic cancers. The program is also involved with the Radiation Therapy Oncology Group (RTOG). Both are cooperative research groups funded by the National Cancer Institute.

Our physicians are also working to establish a Women’s Health Research Initiative and a tissue bank to advance the understanding of female cancers.

Ongoing studies provide access to the best research has to offer in advanced treatments and improved quality of life.

The following clinical trials are open to enrollment.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.

Type of CancerProtocol ID & Study Title
Cancer PreventionNRG-CC008
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]
CervicalIovance-C-145-04
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma

Keywords: Cervical cancer, recurrent , metastatic, LN-145, TILs
Endometrial NRG-GY020
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Keywords: Endometrial Neoplasms, Endometrioid Carcinoma, Adenocarcinoma, Glandular and Epithelial Neoplasms, Uterine Neoplasms, Female Genital Neoplasms, Urogenital Neoplasms, Ovarian Neoplasms, Pembrolizumab
Any cancer being treated with carboplatinNRG-GY022
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Keywords: dMMR, DNA mismatch repair, Mismatch Repair Deficient, Early Stage, High Intermediate Rick, newly diagnosed, Pembrolizumab, Immunotherapy
Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CELSION-201-17-201
Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
EndometrialSutro- STRO-002-GM1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Keywords: Advance Epithelial Ovarian Cancer, Fallopian Tube, Primary Peritoneal and Endometrial Cancer, Folate Receptor Alpha
OvarianGOG-3059
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial
Ovarian GOG 3048
Mersana First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Keywords: Platinum-Resistant, Mersana Therapeutics, XMT-1536 (upifitamab rilsodotin), Antibody-Drug Conjugate (ADC), Early Phase, High Grade Serous, First in Human, Measurable Disease
Ovarian, primary peritoneal, or fallopian tube cancerNRG-GY023
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Keywords: Durvalumab, Olaparib, or Cediranib, Recurrent Platinum Resistant, MEDI4736, Parp Inhibitor, Monoclonal Antibodies, VEGF, High Grade Serous, Grade 3 Endometrioid or Clear Cell Carcinoma, BRCA1 or BRCA2 Mutation
Ovarian, primary peritoneal, or fallopian tube cancerSTRO-002-GM2
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer Ovarian, primary peritoneal, or Fallopian Tube Cancer

Keywords: STRO-002, Phase 1, Bevacizumab, Refractory, Platinum Resistant, Dose Expansion, Anti-Folate Receptor Alpha Antibody Drug Conjugate, Advanced Epithelial Ovarian Cancer, Measurable Disease, High Grade Serous